Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Long-Term Deferred Tax (2016 - 2022)

BioCorRx's Long-Term Deferred Tax history spans 12 years, with the latest figure at $11.4 million for Q4 2023.

  • For Q4 2023, Long-Term Deferred Tax rose 6.82% year-over-year to $11.4 million; the TTM value through Dec 2023 reached $11.4 million, up 6.82%, while the annual FY2023 figure was $11.4 million, 6.82% up from the prior year.
  • Long-Term Deferred Tax for Q4 2023 was $11.4 million at BioCorRx, up from $10.7 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $11.4 million in Q4 2023 and bottomed at $6.4 million in Q4 2019.
  • The 5-year median for Long-Term Deferred Tax is $9.4 million (2021), against an average of $9.0 million.
  • The largest annual shift saw Long-Term Deferred Tax skyrocketed 290.2% in 2019 before it grew 6.82% in 2023.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $6.4 million in 2019, then rose by 12.49% to $7.2 million in 2020, then grew by 29.54% to $9.4 million in 2021, then rose by 14.25% to $10.7 million in 2022, then rose by 6.82% to $11.4 million in 2023.
  • Per Business Quant, the three most recent readings for BICX's Long-Term Deferred Tax are $11.4 million (Q4 2023), $10.7 million (Q4 2022), and $9.4 million (Q4 2021).